Platinum Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Platinum Management’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$14.7M	Buy	778,797 +606,299	+351%	+$11.7M	89.51%	1
2015 Q4	$4.59M	Sell	172,498 -462,818	-73%	-$16.1M	67.86%	1
2015 Q3	$29M	Buy	635,316 +25,700	+4%	+$969K	93.09%	1
2015 Q2	$19.6M	Buy	609,616 +36,874	+6%	+$1.07M	86.22%	1
2015 Q1	$18.2M	Sell	572,742 -157,438	-22%	-$5.33M	94.21%	1
2014 Q4	$27.6M	Sell	730,180 -22,142	-3%	-$609K	59.19%	1
2014 Q3	$19.9M	Buy	752,322 +6,540	+0.9%	+$173K	4.55%	4
2014 Q2	$22.1M	Buy	745,782 +42,110	+6%	+$1.36M	3.13%	7
2014 Q1	$26M	Buy	703,672 +184,906	+36%	+$7.01M	12.3%	1
2013 Q4	$13.5M	Buy	518,766 +50,702	+11%	+$1.98M	19.76%	1
2013 Q3	$24.8M	Buy	468,064 +8,338	+2%	+$486K	13.33%	1
2013 Q2	$24.5M	Buy	+459,726	New	+$23M	8.64%	1

Other funds holding NAVB

Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Platinum Management's NAVB Position: Q1 2016 in Review

Platinum Management increased its Navidea Biopharmaceuticals Inc. (NAVB) stake by 351% in Q1 2016, buying an estimated $11.7M and bringing the position to 778,797 shares worth $14.7M. The position accounts for 89.51% of the portfolio, ranked #1.

Platinum Management first reported a position in NAVB in Q2 2013 and has held it in 12 quarters since. The position peaked at $29M in Q3 2015. 74 funds tracked by Wall St. Rank hold NAVB as of Q1 2016.

Platinum Management held 778,797 shares of Navidea Biopharmaceuticals Inc. worth $14.7M as of Q1 2016.
Platinum Management bought 606,299 Navidea Biopharmaceuticals Inc. shares in Q1 2016, an estimated $11.7M.
Navidea Biopharmaceuticals Inc. made up 89.51% of Platinum Management's portfolio in Q1 2016, its #1 holding.
Platinum Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and has held it in 12 quarters since.
Platinum Management's Navidea Biopharmaceuticals Inc. position peaked at $29M in Q3 2015.
74 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2016.

Based on Platinum Management's 13F filing for Q1 2016, filed 16 May 2016.